Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Share Option Schemes

15 Feb 2012 07:00

RNS Number : 4324X
Imaginatik PLC
15 February 2012
Β 

ο»Ώ

15 February 2012

Imaginatik plc

("Imaginatik" or the "Company")

Β 

Share Option Schemes

Β 

Imaginatik plc (AIM: IMTK), a leading provider of enterprise innovation services including a range of technology products and consultancy, announces that the remuneration committee of the Board has approved changes to the terms of the existing share options issued by the Company.

Β 

There are currently 27,461,845 options outstanding under the Company's various share option schemes, of which 24,012,500 are held by directors and eligible employees. 12,006,250 of these options have now been cancelled and the exercise price of a further 12,006,250 options, which currently ranges from 2.0p to 2.55p, has been rebased to 1p per share. The mid-market price of the Company's ordinary shares as at close of business on 14 February 2012 was 0.42p.

Β 

In addition, the Company has awarded 64,425,000 new share options to directors and employees with an exercise price of 1p per share ("New Options"):

Β 

a. Matt Cooper, Shawn Taylor, Luis Solis and Nicholas Goss, each being an executive director of the Company, have been granted 17,500,000, 11,125,000, 7,500,000 and 5,000,000 options respectively. The grant of a higher number of options to Mr Cooper and Mr Taylor is in recognition of salary sacrifices on their part during the half-year to 30 September 2011. The share options for Mr Cooper and Mr Taylor will be a combination of options issued under The Imaginatik plc Enterprise Management Incentive Scheme ("EMI scheme") as well as unapproved options. The share options for Mr Goss will all be issued under the EMI scheme. The share options for Mr Solis shall be issued under the Imaginatik 2006 Stock Option Plan.

Β 

b. David Gammon, Simon Charles and Brian Hays, non-executive directors of the Company, have each been granted 2,000,000 share options. The share options for Mr Gammon and Mr Charles shall be issued as unapproved options, and those for Mr Hays shall be issued under the Imaginatik 2006 Stock Option Plan.

Β 

c. Key employees of the Company have been granted 17,300,000 share options under the EMI scheme as well as the Imaginatik 2006 Stock Option Plan.

Β 

The re-based options and the New Options will vest as to 50% two years after grant and 50% three years after grant, subject to certain events as particularised in the scheme rules.

Β 

The remuneration committee considers that the grant of the New Options and the combined re-basing and cancellation of existing options provides the senior management team and employees of the Company with an appropriate and effective incentive for the future.

Β 

In addition to the above grants, Northland Capital Partners Limited has been granted 3,206,451 options over new ordinary shares exercisable at any time at 0.5p per share expiring on 13 February 2017 (in connection with the recent placing and open offer).

Β 

Imaginatik now has 78,087,046 share options in issue, representing approximately 15.22% of the current issued share capital and 13.21% of the fully diluted share capital.

Β 

Executive Directors

Options

Matt Cooper

19,062,500

Shawn Taylor

14,225,000

Luis Solis

9,500,000

Nicholas Goss

5,000,000

Non-Executive Directors

David Gammon

2,000,000

Simon Charles

2,000,000

Brian Hays

2,000,000

Employees

17,643,750

Ex-employees

3,449,345

Northland Capital Partners

3,206,451

Β 

Β 

Β 

Matt Cooper, Shawn Taylor and Luis Solis, Executive Directors of the Company and Mr Andrew Wainwright, a former Executive Director of the Company, are participating in the re-basing of the existing share options to the extent of an aggregate of 8,537,500 options. The re-basing of the share options is deemed to be a related party transaction under the AIM Rules for Companies. Nicholas Goss, Brian Hays and David Gammon, the independent directors of the Company for the purposes of the transaction, having consulted with the Company's Nominated Adviser, Northland Capital Partners Limited, consider that the terms of the re-basing of the existing share options are fair and reasonable so far as the shareholders of the Company are concerned.

Β 

Matt Cooper, Executive Chairman of Imaginatik, commented, "Following a comprehensive review of the Company's share option schemes, we are pleased to have put in place a revised share option structure that we believe properly incentivises our employees to build the Company in the long term."

Β 

For further information please contact:

Β 

Imaginatik plc

Tel: 020 7917 2975

Matt Cooper, Executive Chairman / Shawn Taylor, CFO

Northland Capital Partners Limited

Tel: 020 7796 8800

Gavin Burnell / Edward Hutton

Newgate Threadneedle

Tel: 020 7653 9850

Caroline Evans-Jones / Hilary Millar

Β 

About Imaginatik

Β 

Imaginatik provides Innovation and Idea management solutions comprised of consultancy, software and program management to deliver innovation outcomes to companies such as The Chubb Group of Insurance Companies, Boeing, Pfizer, Goodyear, Paccar, Kellogg and Cargill. Few companies possess the internal capability to consistently generate fresh ideas, identify those worth pursuing and reliably transform them into real, value-enhancing assets. This is Imaginatik's area of expertise.

Β 

Imaginatik is a public company whose shares are traded on the AIM market of the London Stock Exchange (LSE:IMTK.L) and a World Economic Forum Technology Pioneer with offices in Boston, MA, and London. In 2009, Imaginatik was named as one of the 500 fastest growing technology companies in the EMEA region by Deloitte. For more information, visit www.imaginatik.com.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
RDSLLFVTFRISLIF
Date   Source Headline
27th Sep 20187:30 amRNSSuspension - Imaginatik plc
26th Sep 20187:00 amRNSUpdate on potential equity investment
17th Sep 20187:00 amRNSUpdate on potential equity investment
11th Sep 201811:35 amRNSUpdate regarding Nominated Adviser
11th Sep 20187:00 amRNSFinal Results
4th Sep 20187:00 amRNSUpdate on potential equity investment
29th Aug 20189:22 amRNSHolding(s) in Company
28th Aug 20189:12 amRNSHolding(s) in Company
24th Aug 20183:39 pmRNSHolding(s) in Company
17th Aug 20183:40 pmRNSIssue of Equity
26th Jul 20187:00 amRNSNew Finance Agreement
25th Jul 20181:05 pmRNSStmnt re Share Price Movement
10th Jul 20184:56 pmRNSHolding(s) in Company
10th Jul 20189:48 amRNSHolding(s) in Company
10th Jul 20187:00 amRNSAppointment of CEO
3rd Jul 20185:45 pmRNSHolding(s) in Company
3rd Jul 20187:00 amRNSIssue of Equity
29th Jun 201810:46 amRNSResult of General Meeting and Total Voting Rights
22nd Jun 20187:00 amRNSContract Win
18th Jun 201812:59 pmRNSHolding(s) in Company
15th Jun 20187:00 amRNSRelease of mobile update to Innovation Central
14th Jun 20187:00 amRNSPosting of circular and notice of general meeting
5th Jun 20185:40 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSResult of strategic review and new funding
29th May 20187:00 amRNSUpdate on sales process and funding
1st May 20187:00 amRNSTrading Statement
21st Mar 20187:00 amRNSUpdate on strategic review and formal sale process
14th Feb 201812:38 pmRNSForm 8.3 - [Imaginatik plc]
12th Feb 20185:51 pmRNSForm 8.3 - Imaginatik plc
9th Feb 20185:50 pmRNSForm 8.3 - Imaginatik
9th Feb 20185:48 pmRNSForm 8.3 - Imaginatik
8th Feb 20183:36 pmRNSHolding(s) in Company
1st Feb 20183:04 pmRNSForm 8 (DD) - Imaginatik plc
1st Feb 201811:36 amRNSForm 8.3 - Imaginatik PLC
1st Feb 20187:00 amRNSForm 8 (OPD) - Imaginatik plc
1st Feb 20187:00 amRNSStrategic review including formal sale process
7th Dec 20177:00 amRNSHalf-year Report
29th Sep 20177:00 amRNSGrant of Options
27th Sep 20177:00 amRNSContract Win
20th Sep 20179:37 amRNSHolding(s) in Company
7th Sep 20175:50 pmRNSResult of AGM
15th Aug 20178:00 amRNSNotice of AGM
7th Aug 20177:00 amRNSFinal Results
10th Jul 201710:47 amRNSHolding(s) in Company
5th Jul 20174:32 pmRNSHolding(s) in Company
4th Jul 20179:51 amRNSHolding(s) in Company
4th Jul 20177:00 amRNSHolding(s) in Company
3rd Jul 201711:10 amRNSResult of Open Offer and Total Voting Rights
27th Jun 20177:00 amRNSResult of GM and Total Voting Rights
9th Jun 20171:04 pmRNSPlacing and Open Offer to raise up to £1.9 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.